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Objectives: In the last decade awareness has been raised due to unsafe and 
dangerous devices entering the European market, putting patient safety at stake. 
Consequently, evidence requirements may not be enough to ensure a high-quality 
and safe provision of medical devices in Europe.This research aims at exploring the 
authorization and reimbursement processes and the associated evidence require-
ments comparing four high-impact regions Europe, United States, Australia and 
Canada. MethOds: First, we performed a literature search about the authorization 
and reimbursement in the four high-impact regions. Second, seven high-risk medi-
cal devices were chosen as examples and current authorization and reimbursement 
status were assessed. Information was extracted from publicly available summaries, 
from PubMed, and from the clinical trial database (clincialtrial.gov), supplemented by 
the worldwideweb. Results: The evidence required for the authorization and reim-
bursement processes clearly differs in the four high-impact regions. All seven devices 
have been authorized in Europe, three in Australia, one in the United States, and one 
in Canada. Currently none of the seven devices is recommended for reimbursement 
in the four high-impact regions. cOnclusiOns: Looking at the difference in evidence 
requirements, more harmonization, transparency and specific regulations are needed 
worldwide for the authorization and reimbursement of high-risk medical devices to 
ensure a high-quality and safe provision.
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Objectives: External reference pricing (ERP) is one of most common cost-contain-
ment tools used to reduce prices for in-patent pharmaceuticals in the European 
Union Member States (MS). The objective of this project was to provide an overview 
of ERP systems, both on processes and potential issues related to ERP systems in 31 
European countries (28 EU MS, Iceland, Norway and Switzerland) (performed for the 
EU Commission). MethOds: A systematic structured literature review and consulta-
tion of representatives of competent authorities and international organizations were 
conducted to identify and characterize the use of ERP, to describe its impacts on the 
prices of pharmaceuticals and to discuss possible cross-country coordination issues 
in EU MS. Results: All selected countries apply ERP except the UK and Sweden and 
23 countries use ERP as main systematic criterion. ERP is based on legislated pricing 
rules with different levels of accuracy in the majority of European countries using 
ERP. ERP is applied either to all marketed drugs or to specific categories of medicines, 
mainly used for publicly reimbursed medicines. The number of reference countries 
included in the basket varies from 1 to 31. There is a great variation in calculation 
methods used to compute the price; 15 countries use average price, 7 countries use the 
lowest price, and 7 countries use other calculation methods. Among reported limita-
tions of ERP application are reliable sources of price information, price heterogeneity, 
exchange rate volatility, and hidden discounts. Spill-over effects on other countries 
and downward price convergence have often been argued leading to pricing strategies 
from pharmaceutical companies. cOnclusiOns: While ERP is widely used in Europe, 
processes and available price information vary from one country to another that may 
limit ERP application. Moreover, ERP spill-over effect is a major concern of pharmaceu-
tical firms leading to implementation of the so-called “launch sequence strategies”.
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Objectives: In Korea, the positive list system (PLS) was introduced in 2007 to 
ensure the good value for money in pharmaceutical expenditure. This study aims 
to investigate factors that are most influential in reimbursement decisions under 
the PLS. MethOds: To assess the 5 years operations and compare the results 
before and after the PLS, we analyzed the drug prices submitted from the com-
panies, the reimbursement decisions made by Pharmaceutical Benefit Coverage 
Assessment Committee (PBCAC). We extracted data from published evaluation 
reports, PBCAC meeting minutes, and internal documents of Health Insurance 
Review and Assessment Service. Results: Under the PLS, 71% of submitted drugs 
were recommended for reimbursement during January 2007- April 2012. For sub-
missions demonstrated superiority or non-inferiority in clinical benefit, 79% of 
submissions were decided to be reimbursed. However, submissions with inferiority 
or uncertainties in clinical benefit were rejected regardless of the price. Comparing 
the negotiated price under the PLS to the relative price under the negative system, 
the negotiated price was 85% of the relative price. The probability of recommenda-
tion was high when ICER was under the GDP per capita, nevertheless submissions 
with high uncertainty in cost-effectiveness were rejected. Submissions which had 
low uncertainty and products for severe diseases or rare diseases were recom-
mended for reimbursement despite ICER was high. cOnclusiOns: This study 
confirmed clinical benefit was the main driver of the reimbursement decision 
making. Not only clinical benefit and cost-effectiveness but the disease sever-
ity, the uncertainty of evidence and reimbursement in other countries were also 
considered in the reimbursement decision making process. In addition, the drug 
prices were reduced a little after PLS introduced compared to those under the 
negative list system.
reimbursement decisions. Our objective was to evaluate the lag between a drug’s 
FDA approval and the publication of the first published CUA evaluating the prod-
uct. MethOds: We used the FDA’s website to identify newly-approved drugs from 
2000-2010 (n= 342). For each drug, we searched the Tufts Medical Center Cost-
Effectiveness Analysis Registry and the NHS Economic Evaluation Database for CUAs 
evaluating the drug for the corresponding FDA-approved indication. We included 
drugs with a corresponding CUA in our dataset. When multiple CUAs for a drug 
were available, we included the CUA with the earliest publication date. We used 
multivariate regression to determine factors associated with time to CUA publica-
tion (years). Independent variables included drug approval year, study funder, i.e., 
whether the CUA was supported by industry, and whether the FDA assigned the 
drug priority review status. Results: One hundred and fifty-six (45.6%) drugs in 
our sample had a corresponding CUA. Average time to CUA publication was 4 years 
(standard deviation 2.3 years). We divided drug approvals into three time inter-
vals; 2000-2002 (mean time to CUA publication= 5.3; SD= 2.4), 2003-2006 (mean= 3.9; 
SD= 2.1) and 2007-2010 (mean= 2.4; SD= 0.97). We found that compared to CUAs for 
drugs approved from 2000-2002, time to CUA publication was 1.5 years shorter for 
drugs approved from 2003-2006 (p< 0.001) and 3 years shorter for drugs approved 
from 2007-2010 (p< 0.0001). Source of study support and FDA priority review sta-
tus were not significantly associated with time to publication cOnclusiOns: For 
FDA-approved drugs with a corresponding CUA, we found a substantial time lag 
between FDA approval and CUA publication, suggesting that decision-makers are 
making important drug coverage and reimbursement decisions without published 
cost-effectiveness evidence available. However, the time to CUA publication appears 
to have declined over time.
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Objectives: To measure the trend of price level for anti-infective drugs in Tianjin, 
China from 2006 to 2010 using multiple index methods and to explore measurement 
bias induced by index methods and measurement units. MethOds: Data were 
extracted from inpatient claims in Tianjin Urban Employee Basic Medical Insurance 
database from 2006 to 2010. Laspeyres, Paasches, Fisher and chained Fisher index 
methods were employed to measure the price level. Price indices were calculated 
both at molecule level (defined by active ingredient) and product level (defined by 
molecule, strength, preparation and manufacturer). Units of quantity and price were 
defined as per DDD (Defined Daily Dose), per milligram of active ingredient, and per 
minimum unit separately to calculate the indices. Results: At product level, 367 
constantly used products (26% of total 1422 products) were included in unchained 
indices and 1041 products (73% of total products) were included in chained Fisher 
indices. The results of multiple indices consistently indicated that the price level 
decreased and the decreasing range indicated by different index methods were 
from 16% (Laspeyres-unit index at molecule level) to 27% (Laspeyres-DDD index at 
product level). The price indices at molecule level decreased slower than the coun-
terparts at product level (22% vs. 25% in chained Fisher-DDD index). At molecule 
level, price indices based on per DDD decreased faster than per mg and per unit 
(22%, 21% and 18% in chained Fisher). Laspeyres indices decreased slower than 
Paasches at molecule level while the contrary was the case at product level. The 
results from chained Fisher and unchained counterparts were similar (25% vs. 26% 
at product level). cOnclusiOns: The price level of anti-infective drugs decreased 
heavily in Tianjin, China. The chained indices were similar to the unchained coun-
terparts which suggested that the price of newer and older products decreased at 
similar rate.
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Objectives: To establish performance evaluation model of the Essential Medicine 
System in China based on Data Envelopment Analysis(DEA), evaluate the relative 
efficiency of essential medicines system and analysis the main problem and impact 
factors on it. MethOds: 15 counties in Sichuan province were selected by stratified 
sampling as Decision Making Units(DMUs); for each county, 30% primary health 
care facilities, totally 284 facilities were involved as sample. Questionnaire survey 
was conducted to collect data of input and output indicators in 2010 and 2011 from 
sample facilities. 3 input indicators and 4 output indicators were set based on lit-
erature review, WHO’s National Drug Policies Monitoring Indicators and experiential 
principle of DEA. Excel 2007 was used to encode data, DEAP 2.1 software was used 
to conduct CRS - CCR and VRS - BCC Data Envelopment Analysis, SPSS16.0 was used 
to conduct T-test and multiple linear regression analysis to exam the statistic dif-
ference between 2010 and 2011, and the influencing factors of efficiency. Results: 
For input indicators, the average special funds of Essential Medicine System(x1) in 
15 counties was raised from 0.52 million US$ in 2010 to 0.69 million US$ in 2011
；the average number of essential medicines(x2) and drug delivery companies(x3) 
raised as well. For output indicators, average outpatient cost per visit(y1) and inpa-
tient cost per admission(y2) decreased, while the outpatient visit times(y3) and 
discharge numbers(y4) kept no increasing as expected. The overall efficiency of 
Essential Medicines System in Sichuan province in two years were in relatively 
high level(0.908 in 2010 and 0.832 in 2011). Analysis on technical efficiency, scale 
efficiency, and return to scale showed the main existing problem was insufficient 
utilization of input health care resource. cOnclusiOns: The effectiveness of imple-
mentation of Nation Essential Medicine System has been displayed, but health 
care resources should be adjusted and utilized rationally to improve the overall 
efficiency.
